Veracyte, a company headquartered in San Francisco, CA, offers diagnostic tests through central laboratories in the United States.
7 reports, 2 independent
Updated Aug 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 7
- Developments
- 4
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Veracyte, a company headquartered in San Francisco, CA, offers diagnostic tests through central laboratories in the United States.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Veracyte presented Afirma GRID studies at the Endocrine Society Annual Meeting, which was held in San Francisco on July 9, 2025.Sub-event
- Helix and Veracyte announced a partnership on August 7, 2025, to expand access to genomic insights.Sub-event
Veracyte is headquartered in San Francisco and provides lab testing services across the US.1 source
Veracyte faces revenue concerns but sees growth from Nightingale and advances Umbrella trial.1 source
Keep exploring
The entities involved
-
Veracyte (United States)
company in South San Francisco, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksHere's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today For most investors, how much a stock's price changes over time is important. This factor can impact your investme
- ZacksIs the Options Market Predicting a Spike in Veracyte Stock? Investors in Veracyte, Inc. VCYT need to pay close attention to the stock based on moves in the options market lately. That is because the
- ZacksHere's Why Veracyte (VCYT) is a Strong Momentum Stock For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Many investors also have a g
- ZacksHere's Why Veracyte (VCYT) is a Strong Growth Stock It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investor
- ZacksVeracyte (VCYT) Tops Q2 Earnings and Revenue Estimates Veracyte (VCYT) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.31 per share. This compares to e
- Simply Wall St.Declining Stock and Decent Financials: Is The Market Wrong About Veracyte, Inc. (NASDAQ:VCYT)? With its stock down 21% over the past three months, it is easy to disregard Veracyte (NASDAQ:VCYT). Howe
- ZacksShould You Continue to Hold Veracyte Stock in Your Portfolio Now? Veracyte VCYT is making solid progress in its long-term growth drivers, including in its NIGHTINGALE study for nasal swabs. The compa